Table 3 Subset analyses of overall survival outcomes
OS from the time of initial brain metastasis in patients who: | Median OS, (range), months |
|---|---|
Were treated with anti-CTLA-4 antibody therapy | |
Before the initial brain metastasis (n = 29) | 10.5 (2.0–55.3) |
After the initial brain metastasis (n = 39) | 19.2 (1.2–65.0) |
Were treated with anti-PD-1 antibody therapy | |
Before the initial brain metastasis (n = 1) | 8.5 |
After the initial brain metastasis (n = 28) | 37.9 (5.3–65.0) |
Were treated with BRAF and/or MEK inhibitor therapy | |
Before the initial brain metastasis (n = 16) | 10.9 (2.1–55.3) |
After the initial brain metastasis (n = 24) | 12.7 (2.7–70.9) |